IceCure Medical (ICCM) Projected to Post Earnings on Tuesday

IceCure Medical (NASDAQ:ICCM) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect IceCure Medical to post earnings of ($0.04) per share and revenue of $1.30 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 11:00 AM ET.

IceCure Medical Stock Up 0.2%

Shares of ICCM opened at $0.69 on Friday. The company has a market capitalization of $47.40 million, a price-to-earnings ratio of -2.65 and a beta of 0.29. IceCure Medical has a 52-week low of $0.54 and a 52-week high of $1.53. The stock has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.76.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Virtu Financial LLC bought a new stake in IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned about 0.09% of IceCure Medical as of its most recent filing with the Securities & Exchange Commission. 0.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ICCM has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $2.64.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.